MiNK Therapeutics, Inc.
INKT· Nasdaq
INKTMiNK Therapeutics, Inc.
Filed Aug 13, 2026 · 10-Q · 44 days after period end · 0001193125-26-349309
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Net Income | -$3.13M | -$4.24M | -$2.70M | -$6.20M |
| EPS Diluted | -$0.62 | -$1.06 | -$0.07 | -$0.18 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
MiNK Therapeutics, Inc. · CIK 1840229 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 13, 2026 · 44 d after period end
